{
    "clinical_study": {
        "@rank": "79095", 
        "arm_group": [
            {
                "arm_group_label": "50 Units", 
                "arm_group_type": "Experimental", 
                "description": "PRX-112 50 Units daily for 5 days"
            }, 
            {
                "arm_group_label": "100 Units", 
                "arm_group_type": "Experimental", 
                "description": "PRX-112 100 Units daily for 5 days"
            }, 
            {
                "arm_group_label": "200 Units", 
                "arm_group_type": "Experimental", 
                "description": "PRX-112 200 Units daily for 5 days"
            }, 
            {
                "arm_group_label": "400 Units", 
                "arm_group_type": "Experimental", 
                "description": "PRX-112 400 Units daily for 5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open-label, dose escalation study to evaluate the safety of oral PRX-112 and\n      pharmacokinetics of GCD in subjects with Gaucher disease naive to enzyme replacement\n      therapy.  The dose levels of PRX-112 are 50 units, 100 units, 200 units and 400 units GCD.\n      Subjects will receive once daily oral administrations of PRX-112 for 5 consecutive days at\n      each dose level with a 2-day washout period between doses."
        }, 
        "brief_title": "An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gaucher Disease", 
        "condition_browse": {
            "mesh_term": "Gaucher Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female age 18 or older\n\n          -  Historical diagnosis of Gaucher disease by low leukocyte GCD activity level\n\n          -  Haemoglobin \u2265 10 g/dL\n\n          -  Body mass index (BMI) of 18 kg/m2-30 kg/m2 inclusive\n\n          -  Subject is able to provide written informed consent\n\n          -  Female subjects of child bearing potential must not be pregnant or lactating with a\n             negative urine pregnancy test result at the screening visit.\n\n          -  Female subjects of child-bearing potential and male subjects with female partners of\n             childbearing potential must use two methods of contraception at all times during the\n             study, one of which must be a barrier method.  Acceptable methods of contraception\n             are oral contraceptives, barrier methods (male condom, female condom, diaphragm,\n             cervical cap, spermicide or intrauterine device), surgical sterility (documented\n             doctor's report of vasectomy, hysterectomy and/or bilateral oophorectomy) and/or\n             postmenopausal status (defined as at least 1 year without menses as demonstrated by\n             medical history or subject report).\n\n          -  Negative laboratory tests for HIV, HBsAg and HCV at the screening visit\n\n          -  Na\u00efve to any previous ERT or have received the last ERT treatment 12 months before\n             signing IC\n\n        Exclusion Criteria:\n\n          -  Presence of a gastrointestinal (GI) disease affecting motility or absorption\n\n          -  Subjects with any history of allergic response to biological drugs or other allergies\n             deemed clinically significant by the Investigator\n\n          -  Reported history of alcohol or drug abuse\n\n          -  Subject has donated blood in the 3 months prior to screening or subject has received\n             plasma derivatives in the 6 months prior to screening\n\n          -  Use of any investigational drug or participation in another clinical trial in the 3\n             months prior to screening (subject report)\n\n          -  Subjects who have previously received ERT with positive anti-human plant recombinant\n             GCD (prGCD) antibodies\n\n          -  Clinical evidence of any active significant disease that could potentially compromise\n             the ability of the Investigator to evaluate or interpret the effects of the study\n             treatment on safety assessment, thus increasing the risk to the subject to\n             unacceptable levels\n\n          -  Presence of any medical, emotional, behavioural or psychological condition that, in\n             the judgement of the Investigator, would interfere the compliance requirements of the\n             study\n\n          -  Subject has used any medication (excluding acetaminophen or dyprione) within 7 days\n             of screening, including laxatives, teas and food additives known to be used for the\n             treatment of constipation or diarrhea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107846", 
            "org_study_id": "PB-112-02a"
        }, 
        "intervention": {
            "arm_group_label": [
                "50 Units", 
                "100 Units", 
                "200 Units", 
                "400 Units"
            ], 
            "intervention_name": "PRX-112", 
            "intervention_type": "Drug", 
            "other_name": "Carrot Cells Expressing Recombinant Human Glucocerebrosidase"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "azimran@gmail.com", 
                "last_name": "Ari Zimran, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Jerusalem", 
                    "country": "Israel"
                }, 
                "name": "Shaare Zedek Medical Center"
            }, 
            "investigator": {
                "last_name": "Ari Zimran, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Na\u00efve Subjects With Gaucher Disease", 
        "overall_contact": {
            "email": "alona.paz@protalix.com", 
            "last_name": "Alona Paz, MD", 
            "phone": "+972-4-902-8100", 
            "phone_ext": "261"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Blood samples for GCD level every 2 hours for 24 hours", 
                "measure": "Area under the curve", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Reporting of adverse events collected daily", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "7 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107846"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Protalix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protalix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}